Mantle Cell Lymphoma Excellence Forum

Mantle Cell Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Treatment Approaches for Patients With Untreated and Relapsed MCL

05/23/2022

Tycel Phillips, MD, reviews standard therapies utilized for patients with MCL, including nonaggressive regimens and BTK inhibitor therapies.

Tycel Phillips, MD, reviews...

05/23/2022

Oncology

Preetesh Jain, MD, PhD, University of Texas MD Anderson Cancer Center

Videos

Ibrutinib Plus Rituximab Demonstrates Promising Efficacy in Older Patients With Previously Untreated MCL

05/15/2022

Preetesh Jain, MD, discusses results from a phase 2 trial exploring the efficacy and safety of ibrutinib plus rituximab for the first-line treatment of older patients with MCL.

Preetesh Jain, MD, discusses...

05/15/2022

Oncology

Videos

3D Cultivation Improves Survival Time of Primary Mantle Cell Lymphoma Cells, Enables Long-term Experiments

04/30/2022

Kathrin Böpple, PhD, and Meng Dong, PhD discuss the development of a 3D cultivation system with alginate hydrogel that improves the in vitro survival time of primary mantle cell lymphoma cells.

Kathrin Böpple, PhD, and Meng...

04/30/2022

Oncology

Videos

Study Profiles T-Cell Subpopulations Based on Spatial Proteome in MCL

04/18/2022

Lavanya Lokhande, PhD, discusses results from a study, presented at the AACR Annual Meeting, which investigated T-cell subpopulations profiled by spatial proteome among patients with MCL.

Lavanya Lokhande, PhD, discusses...

04/18/2022

Oncology

Videos

Loss of GTPase RhoA Impairs Lenalidomide Activity in MCL

04/18/2022

Gaël Roué, PhD, highlights a study providing insight into how the loss of the small GTPase RhoA enhances lymphomagenesis and impairs the activity of lenalidomide in patients with MCL.

Gaël Roué, PhD, highlights a...

04/18/2022

Oncology

Videos

Impact of CD163-Positive Cells on MCL Development and Treatment Response

04/13/2022

A study presented at the AACR Annual Meeting demonstrates that spatial localization within the MCL tumor affects the expression of CD163-positive macrophages and identifies possible targetable markers.

A study presented at the AACR...

04/13/2022

Oncology

Videos

Dr Aroldi Overviews CD24 ‘Don’t Eat Me’ Signal as a Potential Immunotherapeutic Target for MCL

03/29/2022

Andrea Aroldi, MD, overviews the CD24 ‘don’t eat me’ signal immune checkpoint blockade as a potential immunotherapeutic target for MCL, presented at ASH 2021.

Andrea Aroldi, MD, overviews the...

03/29/2022

Oncology

Conference Insider

Dr Martin Discusses How to Approach MCL

03/23/2022

Emily Bader ;

Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.

Peter Martin, MD, discusses how...

03/23/2022

Oncology

Videos

Dr Lee Reviews Cirmtuzumab and Ibrutinib in MCL/CLL

03/02/2022

Hun Ju Lee, MD, reviews a phase 1b/2 study of cirmtuzumab and ibrutinib for patients with MCL or CLL.

Hun Ju Lee, MD, reviews a phase...

03/02/2022

Oncology

Videos

Dr Beitinjaneh Highlights Brexucabtagene Autoleucel for R/R MCL

02/10/2022

Amer Beitinjaneh, MD, MPH, MSc, highlights a multicenter retrospective study on brexucabtagene autoleucel, which was approved by the FDA in July 2020 and demonstrates encouraging safety and efficacy, for R/R MCL.

Amer Beitinjaneh, MD, MPH, MSc,...

02/10/2022

Oncology

Recent News

Conference Insider

Dr Martin Discusses How to Approach MCL

03/23/2022

Emily Bader ;

Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.

Peter Martin, MD, discusses how...

03/23/2022

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology